Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

Michael O'Riordan

March 25, 2022

News Conference News ACC 2021

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

Caitlin E. Cox

May 25, 2021

News Conference News ACC 2019

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

Michael O'Riordan

March 21, 2019

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Presenter: Matthias Götberg

March 20, 2017

Presentation ACC 2017

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Presenter: Pieter Smits

March 20, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

Presentation ACC 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presenter: Justin E Davies

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

News Conference News ACC 2017

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

Todd Neale

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Advertisement

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Nitroglycerin Given Early or Late Fails to Prevent Radial Artery Occlusion: PATENS

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

The RAD-MATRIX Study

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content